Medicine compounds for treating osteoporosis

A technology of osteoporosis and composition, which is applied in the direction of drug combination, drug delivery, bone diseases, etc., can solve the problem that the pathogenesis is not fully studied, and achieve remarkable curative effect, convenient drug use, and reduce side effects

Active Publication Date: 2008-07-30
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Osteoporosis is a chronic and intractable disease, and its pathogenesis has not been fully studied, so there is no ideal drug for the treatment of osteoporosis in clinical practice.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine compounds for treating osteoporosis
  • Medicine compounds for treating osteoporosis
  • Medicine compounds for treating osteoporosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1 Effects of strontium ranelate and alendronate sodium compound on castrated osteoporosis model rats

[0016] 1. Experimental materials and methods

[0017] 1) Experimental drugs

[0018] Alendronate Sodium, Strontium Ranelate.

[0019] 2) Experimental animals and modeling methods

[0020] 50 6-month-old female sterile SD rats (provided by Lunan Pharmaceutical Group New Times Pharmaceutical Animal Center, SPF grade).

[0021] Modeling method: firstly, rats were anesthetized with 100g / L chloral hydrate, injected intraperitoneally at 300mg / kg, and bluntly separated the abdominal muscle and retroperitoneum into the abdomen through a midline incision, found the ovary, ligated it with silk thread, and sutured the incision. The sutures were removed 1 week later.

[0022] 3) Grouping

[0023] random grouping;

[0024] Group A: model control group, 10 rats, the anesthesia method and operation path were the same as the modeling method above, ovariectomized, intraga...

Embodiment 2

[0047] Example 2 Effects of strontium ranelate and alendronate sodium compound on osteoporosis rats modeled with retinoic acid

[0048] 1. Experimental method

[0049]Fifty 6-month-old female SD rats, weighing between 180 and 220 g, were selected from the Experimental Animal Center of Lunan Pharmaceutical Group and randomly divided into 5 groups:

[0050] Blank control group: 10 rats were given intragastric administration of 2ml of 1% sodium carboxymethylcellulose saline, once a day.

[0051] Retinoic acid-induced osteoporosis model group: 10 rats were intragastrically administered with 2ml of 4% retinoic acid suspension prepared by adding 1% carboxymethylcellulose sodium solution and retinoic acid, once a day.

[0052] Strontium ranelate and alendronate sodium compound group: 10 rats, as above modeling method, add strontium ranelate and alendronate sodium solution with 1% sodium carboxymethylcellulose solution to make a solution, press ranelate Strontium 700mg / kg + alendron...

Embodiment 3

[0071] The preparation of embodiment 3 strontium ranelate and alendronate sodium granules

[0072] Strontium ranelate 2000g

[0073] Alendronate Sodium 5g

[0074] Mannitol 2000g

[0075] Corn starch 2000g

[0076] Sucrose 8000g

[0077] Sodium Carboxymethyl Cellulose 800g

[0078] 10% starch slurry appropriate amount

[0079] Preparation Process:

[0080] Pass strontium ranelate, sodium alendronate, mannitol, cornstarch, sucrose, and sodium carboxymethylcellulose in the prescription through a 100-mesh sieve, weigh according to the prescription, mix well, and add 10% starch slurry to prepare To make soft material, granulate with 14 mesh sieve, dry at 70-80°C, granulate with 12 mesh sieve, and pack.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a medical compound for treating osteoporosis which is characterized in that the invention contains strontium ranelate and bisphosphonate. Animal experiments indicate that the invention achieves the unexpected effect for treating the osteoporosis. The osteoporosis is a bone disease of the whole body characterized by the low bone mass and the degeneration of the micro structure of the bone organization, companying with the enhancement of the bone fragility and easy happened bone broken for which no ideal treatment medicine exists in the clinic. The bisphosphonate of the invention comprises alendronate, risedronate sodium, ibandronate, pamidronate, Etidronate, disodium clodronate and zoledronic acid, etc. In the invention, the dosage of the bisphosphonate is greatly reduced, which can effectively reduce the happening of side effects and is convenient to use the medicine.

Description

technical field [0001] The invention belongs to a new western medicine compound. Background technique [0002] Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural degeneration of bone tissue, accompanied by increased bone fragility and susceptibility to fracture. Osteoporosis can be divided into primary and secondary types, among which primary osteoporosis accounts for about 95% of osteoporosis, and it can be divided into two subtypes, namely type I and type II type. Type I is also called postmenopausal osteoporosis, and type II is senile osteoporosis. Secondary osteoporosis can be secondary to other diseases or caused by drugs. Bone strength and integrity depend on a balance between bone resorption by osteoclasts from the hematopoietic tissue and remodeling by osteoblasts from the marrow stroma. With aging or due to diseases, drugs and other reasons, bone resorption exceeds bone formation, bone loss will occur, and secondary...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/663A61K9/08A61K9/10A61K9/16A61K9/20A61K9/48A61P19/10A61K31/381
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap